An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Curio Bioscience reported a favorable decision from the European Unified Patent Court (UPC) regarding a patent infringement claim by 10x Genomics. The court found that Curio Seeker does not infringe on the main claim asserted by 10x Genomics and ordered Curio Bioscience not to offer any violating products in certain countries. Curio Bioscience expects no impact on its commercial business due to this ruling.
Curio Bioscience ha ricevuto una decisione favorevole dalla Corte Unificata dei Brevetti Europea (UPC) in merito a una denuncia di violazione di brevetto da parte di 10x Genomics. La corte ha stabilito che il Curio Seeker non viola la rivendicazione principale avanzata da 10x Genomics e ha ordinato a Curio Bioscience di non offrire prodotti che violino il brevetto in alcuni paesi. Curio Bioscience prevede che questa sentenza non avrà impatti sul suo business commerciale.
Curio Bioscience ha recibido una decisión favorable del Tribunal Unificado de Patentes Europeo (UPC) respecto a una demanda por infracción de patente presentada por 10x Genomics. El tribunal determinó que Curio Seeker no infringe la reivindicación principal de 10x Genomics y ordenó a Curio Bioscience no ofrecer productos que violen el patente en ciertos países. Curio Bioscience no espera impactos en su negocio comercial debido a este fallo.
큐리오 바이오사이언스는 10x 제노믹스가 제기한 특허 침해 주장에 대해 유럽 통합 특허 법원(UPC)으로부터 유리한 판결을 받았습니다. 법원은 큐리오 시커가 10x 제노믹스가 주장한 주요 주장을 침해하지 않는다고 판단하고 특정 국가에서 위반 제품을 제공하지 않도록 큐리오 바이오사이언스에 명령했습니다. 큐리오 바이오사이언스는 이 판결이 그들의 상업적 사업에 영향을 미치지 않을 것으로 예상합니다.
Curio Bioscience a reçu une décision favorable de la Cour de brevets unifiée européenne (UPC) concernant une réclamation pour violation de brevet par 10x Genomics. Le tribunal a conclu que le Curio Seeker ne porte pas atteinte à la revendication principale de 10x Genomics et a ordonné à Curio Bioscience de ne pas offrir de produits en violation dans certains pays. Curio Bioscience ne prévoit aucun impact sur son activité commerciale suite à cette décision.
Curio Bioscience hat eine positive Entscheidung vom Einheitlichen Patentgerichtshof (UPC) bezüglich einer Patentverletzungsklage von 10x Genomics erhalten. Das Gericht hat festgestellt, dass der Curio Seeker den Hauptanspruch von 10x Genomics nicht verletzt und Curio Bioscience angewiesen, keine verletzenden Produkte in bestimmten Ländern anzubieten. Curio Bioscience erwartet durch dieses Urteil keine Auswirkungen auf sein Geschäft.
Positive
The court ruled in favor of Curio Bioscience, stating that Curio Seeker does not infringe the main claim of EP 2697391 asserted by 10x Genomics.
Curio Bioscience expects no negative impact on its commercial business in France, Germany, and Sweden, where the court order is applicable.
Negative
None.
Court finds non-infringement by Curio Seeker with respect to over-reaching claim by 10x Genomics
PALO ALTO, Calif.--(BUSINESS WIRE)--
Curio Bioscience, a leading innovator of high-precision tools for the life sciences industry, today announced that a decision in a court case has been made.
The European Unified Patent Court (UPC) today announced a finding that Curio Seeker does not infringe main claim 1 of EP 2697391 asserted by 10x Genomics (NASDAQ: TXG). The UPC has also ordered Curio Bioscience not to offer any product that would violate claim 14 of the ‘391 patent in France, Germany, and Sweden. Accordingly, Curio Bioscience will comply with the order and expects no impact to its commercial business.
This ruling is restricted to the three countries mentioned and does not affect Curio’s activities elsewhere, nor does it impact other Curio products.
The decision arises from 10x’s request for provisional measures and is open to appeal. The main action remains pending.
What is the recent decision announced by the European Unified Patent Court (UPC) concerning Curio Bioscience and 10x Genomics?
The UPC found that Curio Seeker does not infringe main claim 1 of EP 2697391 asserted by 10x Genomics.
Which countries are affected by the court order against Curio Bioscience regarding the '391 patent?
France, Germany, and Sweden are the countries where Curio Bioscience is ordered not to offer any product that would violate claim 14 of the '391 patent.
Is the ruling from the European Unified Patent Court binding for all countries where Curio Bioscience operates?
No, the ruling is restricted to France, Germany, and Sweden, and does not affect Curio's activities elsewhere or impact other Curio products.
Is the decision final, or can it be appealed?
The decision is open to appeal, and the main action remains pending despite the ruling on provisional measures.
What is the potential impact of the court decision on Curio Bioscience's commercial business?
Curio Bioscience expects no impact on its commercial business due to the court ruling in its favor.
advancing human health requires a greater understanding of biology, and that understanding starts with the cell. we enable researchers to drive exponential progress in oncology, immunology, neuroscience, and more with novel single cell, spatial, and in situ tools that have been cited in over 3,000 publications and continually improved by our dedicated scientific team. our aim: to develop innovative instruments, reagents, and software that allow you to see your biological system at a resolution that matches its complexity.
